Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNK08954 Food Effect and Mass Balance Study
NCT07334262Phase 1Not yet recruiting
- Sponsor
- Ranok Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RNK08954 in solid tumor, pancreatic cancer (PC), colorectal cancer (CRC) and 1 more, sponsored by Ranok Therapeutics. Primary endpoints: Time to Maximum Plasma Concentration at 30 days, Lag Time at 30 days and 3 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
RNK08954
03
Conditions
solid tumorpancreatic cancer (PC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07334262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334262.